Jeffrey M. Silberberg

Jeffrey M. Silberberg

Hematology | Oncology
326 Professional View Dr
Bldg 300
Freehold, NJ 07728

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1 publications

Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.

Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: March 31, 2018
Showing 1-1 of 1

Last Updated: 09/26/2026